Elinzanetant

Major

Elinzanetant Clindamycin ANTIROBE Explained Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Colchicine Colcrys Explained Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Abemaciclib Verzenio Explained Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Acalabrutinib Calquence Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Axitinib Inlyta Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Bosutinib Bosulif Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Brigatinib Alunbrig Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Clindamycin Injection ANTIROBE Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Clindamycin Topical C/T/S® Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Clindamycin Vaginal Cleocin Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Cobimetinib Cotellic Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Cyclosporine Injection Atopica Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Cyclosporine Ophthalmic Cequa Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Dasatinib Phyrago Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Dexamethasone Injection Decadron Reduced elinzanetant exposure and reduced efficacy of elinzanetant Details Elinzanetant Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced elinzanetant exposure and reduced efficacy of elinzanetant Details Elinzanetant Dihydroergotamine Injection DHE-45® Injection Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Dihydroergotamine Nasal Spray Migranal Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Docetaxel Beizray Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Docetaxel Injection Beizray Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Dofetilide Tikosyn Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Encorafenib Braftovi Reduced elinzanetant exposure and reduced efficacy of elinzanetant Details Elinzanetant Entrectinib Rozlytrek Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Everolimus Afinitor Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Fentanyl Transdermal Patch Duragesic® Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Ketoconazole Topical Extina® Foam Increased elinzanetant exposure and an increased risk of elinzanetant-related adverse reactions Details Elinzanetant Lefamulin Xenleta Increased elinzanetant exposure and an increased risk of elinzanetant-related adverse reactions Details Elinzanetant Lenacapavir Injection Sunlenca Increased elinzanetant exposure and an increased risk of elinzanetant-related adverse reactions Details Elinzanetant Lenacapavir Oral Sunlenca Increased elinzanetant exposure and an increased risk of elinzanetant-related adverse reactions Details Elinzanetant Letermovir Injection Prevymis Increased elinzanetant exposure and an increased risk of elinzanetant-related adverse reactions Details Elinzanetant Midostaurin Rydapt Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Mitapivat Aqvesme Reduced elinzanetant exposure and reduced efficacy of elinzanetant Details Elinzanetant Nafcillin Injection Unipen® Injection Reduced elinzanetant exposure and reduced efficacy of elinzanetant Details Elinzanetant Neratinib Nerlynx Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Elinzanetant Olaparib Lynparza Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details